Corvus Pharmaceuticals has reported final peer-reviewed Phase 1/1b findings showing durable responses with oral ITK inhibitor soquelitinib in heavily pretreated patients with T-cell lymphomas, including complete responses lasting more than two years in some patients. Published in Blood, the journal of the American Society of Hematology, the dataset provides the clinical and mechanistic foundation for Corvus Pharmaceuticals’ ongoing registration Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma while strengthening the company’s argument that selective ITK inhibition could have applications beyond oncology.
The early-stage study enrolled 75 patients across several T-cell lymphoma subtypes, most of whom had already received multiple therapies. Among a selected subgroup treated with soquelitinib 200 milligrams twice daily after one to three previous therapies, the objective response rate reached 37.5%, including six complete responses, while median overall survival reached 28.1 months. The results remain preliminary because the study was non-randomized and involved relatively small patient groups, making the ongoing Phase 3 comparison the more consequential test of whether soquelitinib can improve outcomes against existing therapies.
Final Phase 1/1b results provide a clearer picture of soquelitinib activity in difficult-to-treat T-cell lymphoma
The completed Phase 1/1b program included patients with peripheral T-cell lymphoma, T follicular helper cell lymphoma, natural killer T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma and adult T-cell lymphoma or leukemia. Participants had received a median of three previous therapies, with the number ranging as high as 18, underscoring the treatment-resistant population evaluated in the study. Only 31% had achieved an objective response to their most recent prior therapy before entering the soquelitinib trial.
During dose escalation, patients received soquelitinib twice daily at doses ranging from 100 milligrams to 600 milligrams. Corvus Pharmaceuticals ultimately selected 200 milligrams twice daily for dose expansion after biomarker studies indicated that doses at or above that level achieved complete occupancy of the drug’s ITK target.
Thirty-six patients were subsequently treated at the selected 200-milligram twice-daily dose. Across that group, investigators observed six complete responses and three partial responses, providing evidence of antitumor activity despite the advanced and heavily pretreated nature of the study population.
Corvus Pharmaceuticals identified patients who had received between one and three previous therapies as the subgroup most likely to respond. Among 24 such patients, nine achieved an objective response, consisting of six complete responses and three partial responses. Median progression-free survival reached 6.2 months, while approximately 30% of patients remained progression-free at 18 months.
Median overall survival in that subgroup reached 28.1 months, with 67% of patients alive at 24 months. Those figures are notable relative to the historical outcomes cited by Corvus Pharmaceuticals for relapsed or refractory peripheral T-cell lymphoma, where median progression-free survival is generally around three to four months and median overall survival can range from approximately six to 12 months. Cross-trial comparisons require substantial caution, however, because differences in patient selection, prior therapies and study design can make apparently favorable comparisons misleading.
Durable complete responses strengthen the rationale for testing soquelitinib against established salvage therapies
The durability of several responses may be one of the more important aspects of the final dataset. Corvus Pharmaceuticals reported that some complete responses continued beyond two years, suggesting that a subset of patients may experience prolonged disease control after selective ITK inhibition.
That durability matters in peripheral T-cell lymphoma because patients who relapse after initial therapy often face limited options and poor long-term outcomes. Approximately three-quarters of patients either fail to respond to first-line treatment or relapse within the first two years, according to background information provided by Corvus Pharmaceuticals.
Soquelitinib is now being evaluated in a randomized registration Phase 3 trial expected to enroll approximately 150 patients with relapsed or refractory peripheral T-cell lymphoma. The study compares soquelitinib with physician’s choice of either belinostat or pralatrexate, with progression-free survival serving as the primary endpoint.
That randomized design should provide a much clearer assessment than the Phase 1/1b study of whether the apparent clinical activity translates into a genuine treatment advantage. Corvus Pharmaceuticals reported earlier in August that enrollment remained on track, with an interim futility analysis expected in the first quarter of 2027.
The United States Food and Drug Administration has already granted soquelitinib Orphan Drug Designation for T-cell lymphoma and Fast Track designation for adults with relapsed or refractory peripheral T-cell lymphoma following at least two systemic treatment lines. Those designations do not indicate that approval is likely, but they reflect the unmet need within the indication and could facilitate regulatory interactions if Phase 3 results are positive.
Selective ITK inhibition could give Corvus a mechanism spanning oncology and inflammatory disease
Soquelitinib’s development strategy extends beyond its observed tumor responses. The oral small molecule selectively inhibits interleukin-2-inducible T-cell kinase, an enzyme expressed predominantly in T cells that plays a role in T-cell and natural killer-cell immune function.
Corvus Pharmaceuticals’ mechanistic work suggests that ITK inhibition can shift T-cell differentiation toward the Th1 phenotype while suppressing Th2 and Th17 pathways. Th1 cells contribute to immune responses against tumors and infections, whereas excessive Th2 and Th17 activity is implicated in several allergic, autoimmune and inflammatory disorders.
Biomarker analyses from the lymphoma study provided evidence consistent with that mechanism. Patient blood and tumor samples showed increased Th1 activity and reduced serum interleukin-5, while RNA sequencing of paired tumor biopsies from six patients identified increased intratumoral Th1 cells after treatment.
The findings suggest that soquelitinib could potentially exert both direct effects on malignant T cells and indirect effects by modifying the immune environment surrounding tumors. That dual mechanism is one reason Corvus Pharmaceuticals is investigating the same compound across diseases that may initially appear unrelated.
A randomized Phase 2 study, SIERRA1, is already evaluating soquelitinib in atopic dermatitis, with top-line results expected during the third quarter of 2027. Corvus Pharmaceuticals is also planning development in hidradenitis suppurativa and asthma, creating the possibility that successful ITK inhibition could support a broader immunology franchise rather than a single oncology indication.
Safety profile remains encouraging, but larger randomized studies will determine the real benefit-risk balance
Soquelitinib was reported to be generally well tolerated across doses as high as 600 milligrams twice daily. Corvus Pharmaceuticals said investigators observed no dose-limiting toxicities and highlighted the absence of significant myelosuppression or immunosuppression during the Phase 1/1b study.
That profile could prove commercially relevant if it persists because many patients with relapsed T-cell lymphoma have already received therapies associated with considerable hematologic toxicity. An oral therapy capable of producing durable responses without substantial bone marrow or immune suppression could offer a useful treatment characteristic.
The limitations of early-stage safety data remain important, however. Rare adverse events can emerge only after substantially larger patient exposure, while randomized studies are better positioned to distinguish treatment-related events from complications associated with advanced cancer and previous therapies. The registration Phase 3 trial will therefore provide information not only about progression-free survival but also about how soquelitinib’s tolerability compares with established treatment choices in a more controlled setting.
Corvus Pharmaceuticals has sufficient cash runway to reach several critical soquelitinib catalysts
Corvus Pharmaceuticals entered this next stage of development with a materially strengthened balance sheet. The company reported $215.2 million in cash, cash equivalents and marketable securities at June 30, compared with $56.8 million at the end of 2025, largely reflecting approximately $189.4 million in net proceeds from a January financing. Management expects existing resources to fund operations into the second quarter of 2028.
Research and development expenses rose to $16 million during the second quarter from $7.9 million a year earlier as spending increased on soquelitinib clinical programs. The quarterly net loss widened to $18 million from $8 million, illustrating the cost of simultaneously advancing the registration lymphoma study and expanding development into immunology.
The current runway is significant because it potentially allows Corvus Pharmaceuticals to reach the Phase 3 interim analysis and several other soquelitinib milestones without an immediate need for another major financing. Execution risk remains substantial, particularly because the company remains clinical-stage and does not have an approved commercial product generating recurring revenue.
Investor sentiment remains notably positive despite that risk. Corvus Pharmaceuticals shares closed at $14.73 on August 26 after gaining 1.17%, extending the stock’s advance from $12.92 one month earlier. The shares remain well below their 52-week high of $26.95, illustrating the considerable volatility surrounding expectations for soquelitinib.
Analyst coverage is strongly bullish. S&P Global data compiled by StockAnalysis show eight analysts with a consensus Strong Buy rating and an average price target of $33.14, although such targets represent analyst expectations rather than reliable predictions of future share performance. Recent ratings include buy recommendations from Mizuho Securities, H.C. Wainwright, Oppenheimer and Barclays.
The Blood publication adds scientific credibility to a dataset investors have followed for some time, but it does not fundamentally remove the major development risk facing Corvus Pharmaceuticals. The decisive question remains whether soquelitinib can reproduce its early response durability in a randomized Phase 3 setting and outperform established salvage therapies on progression-free survival.
If it does, Corvus Pharmaceuticals could have an oral therapy with a differentiated mechanism in a lymphoma population with limited effective options, while the same ITK biology could support development across several inflammatory diseases. If the Phase 3 study fails to validate the early signal, however, the current valuation and broader platform expectations would face a substantially more difficult test.
